SCHEMBL1821157

SCHEMBL1821157

CC(C)Cc1ccc(C(C)C(=O)Nc2ccncc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.74
CRHBP P24387 2/20 0.74
CRHR2 Q13324 2/20 0.74
GAA P10253 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
RAB9A P51151 2/20 0.74
MAPK1 P28482 1/20 0.70
CA12 O43570 1/20 0.66
CA1 P00915 1/20 0.66
CA2 P00918 1/20 0.66
CA4 P22748 1/20 0.66
CA9 Q16790 1/20 0.66
CHRM1 P11229 1/20 0.63
PDE4A P27815 1/20 0.63
LMNA P02545 3/20 0.62
XBP1 P17861 1/20 0.62
NPSR1 Q6W5P4 1/20 0.59
FAAH O00519 1/20 0.59
CXCR1 P25024 5/20 0.58
CXCR2 P25025 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3156221 1.00 MAPT (0.74) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL13802534 0.87 RAB9A (0.58) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL3151838 0.87 MAPT (0.76) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL4372856 0.87 MAPT (0.76) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL27291251 0.87 MAPT (0.76) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL21620312 0.85 MAPT (0.79) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL3155546 0.82 MAPK1 (0.66) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL3136679 0.82 MAPK1 (1.00) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL7162932 0.82 MAPT (0.73) MAPTCRHBPCRHR2GAASMN1; SMN2
SCHEMBL4746925 0.82 MAPT (0.73) MAPTCRHBPCRHR2GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120316169-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.p.A. (IT) 2012-12-13 US claimed
EP-2493846-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe S.p.A. (IT) 2012-09-05 EP claimed
CN-102656140-A 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them DOMPE SPA 2012-09-05 CN claimed
WO-2011051375-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.p.A. (IT) 2011-05-05 WO claimed
EP-2316820-A1 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them Dompe S.p.A. (IT) 2011-05-04 EP claimed
US-20120316169-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.p.A. (IT) 2012-12-13 US disclosed
US-20120316169-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.p.A. (IT) 2012-12-13 US disclosed
EP-2493846-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe S.p.A. (IT) 2012-09-05 EP disclosed
CN-102656140-A 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them DOMPE SPA 2012-09-05 CN disclosed
WO-2011051375-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.p.A. (IT) 2011-05-05 WO disclosed
WO-2011051375-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.p.A. (IT) 2011-05-05 WO disclosed
EP-2316820-A1 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them Dompe S.p.A. (IT) 2011-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316169-A1 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BDKRB2, BDKRB1, CNR2 MAPT 2858/4885CRHBP 562/4885CRHR2 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.